药物治疗与SPECT心肌灌注显像结果对生存率的相关性
该研究纳入2015年1月至2021年12月因疑似冠心病行SPECT心肌灌注显像的7802例连续患者,采用多变量Cox回归分析药物与全因死亡率的关联。ACE抑制剂/ARB与较低死亡率相关(校正HR 0.66),β受体阻滞剂在缺血更明显患者中与较低死亡率相关,他汀在有冠状动脉钙化患者中与更高生存率相关。
要点
- ACE抑制剂/ARB与较低全因死亡率相关(校正HR 0.66,95%CI 0.57-0.77,P<0.001)。
- β受体阻滞剂总体与死亡率无显著关联,但在缺血更明显患者中与较低死亡率相关(每单位SDS的HR 0.94)。
- 他汀在有冠状动脉钙化患者中与更高生存率相关(校正HR 0.67),无钙化评估者无显著关联。
核心结论
- ACE抑制剂/ARB处方与改善生存率显著相关。
- β受体阻滞剂处方在缺血患者中与更高生存率相关,他汀在冠状动脉钙化患者中与更高生存率相关。
- MPI结果可能识别更可能从特定治疗中获益的患者,提示混合MPI在指导冠心病药物治疗中的作用。
研究设计与样本
- 研究纳入2015年1月至2021年12月因疑似冠心病行单光子发射计算机断层扫描心肌灌注显像的连续患者。
- 采用多变量Cox回归模型评估药物治疗与全因死亡率之间的关联。
- 共纳入7802例患者,平均年龄66.1±12.0岁,男性3841例(49.2%)。
主要发现
- ACE抑制剂/ARB与较低死亡率相关(校正HR 0.66,95%CI 0.57-0.77,P<0.001)。
- β受体阻滞剂总体与死亡率无显著关联(校正HR 0.95,95%CI 0.83-1.10,P=0.506),但在缺血更明显患者中与较低死亡率相关(每单位 summed difference score 的HR 0.94,95%CI 0.90-0.97,P<0.001)。
- 他汀在有冠状动脉钙化患者中与更高生存率相关(校正HR 0.67,95%CI 0.56-0.81,P<0.001),在未评估冠状动脉钙化患者中无显著关联(校正HR 1.16,95%CI 0.91-1.49,P=0.236)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Myocardial perfusion imaging (MPI) results in downstream changes to medication prescription. While the benefits of medical therapy for coronary artery disease (CAD) are established, how this varies with MPI findings is unknown. Our goal was to evaluate the association of medical therapy with survival among patients undergoing MPI, including differential associations as a function of imaging findings. METHODS: Consecutive patients who underwent single-photon emission computed tomography MPI for suspected CAD between January 2015 and December 2021 were identified. Multivariable Cox regression modeling was used to assess the associations between medical therapy and all-cause mortality. RESULTS: In total, 7802 patients were included with a mean age of 66.1 ± 12.0 years and 3841 (49.2 %) male patients. Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACE inhibitors/ARBs) were associated with lower mortality (adjusted hazard ratio [HR] .66, 95 % confidence interval [CI]: .57-.77, P < .001). Beta-blockers were not associated with mortality overall (adjusted HR .95, 95 % CI: .83-1.10, P = .506) but were associated with lower mortality among patients with more ischemia (HR .94 per summed difference score point, 95 % CI: .90-.97, P-value <.001). Statins were associated with greater survival in patients with coronary calcium (adjusted HR .67, 95 % CI .56-.81, P = <0.001) but not in patients without assessment of coronary calcium (adjusted HR: 1.16, 95 % CI: .91-1.49 P = .236). CONCLUSION: ACE/ARB prescription was significantly associated with improved survival. Beta-blocker prescription was associated with greater survival in patients with ischemia and statins were in patients with coronary calcification. Findings from MPI may identify patients more likely to benefit from specific therapies, suggesting a role for hybrid MPI in guiding medical therapy for CAD.
引用
- Hijazi W, Feng Y, Southern DA, et al. Association of medical therapies with survival according to SPECT MPI findings. J Nucl Cardiol. 2025. PMID: 40324562. doi:10.1016/j.nuclcard.2025.102229
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。